Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Type 1 diabetes in DQ8 positive patients with residual beta cell function

4

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor alpha

4

DOPA decarboxylase

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1962

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Abraxis BioScience

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

EPA CompTox

4

EVMPD

4

FDA UNII

4

NCI_THESAURUS

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIHYPERTENSIVES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIADRENERGIC AGENTS, CENTRALLY ACTING

1

ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Methyldopa

1

Methyldopa and diuretics in combination

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

METHYLDOPA ANHYDROUS

M4R0H12F6M

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1962

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha

DOPA decarboxylase

Adrenergic receptor alpha

Conditions:

Type 1 diabetes in DQ8 positive patients with residual beta cell function

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble an...

d stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

METHYLDOPATE

2579Z4P04J

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1962

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha

DOPA decarboxylase

Adrenergic receptor alpha

Conditions:

Type 1 diabetes in DQ8 positive patients with residual beta cell function

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble an...

d stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

METHYLDOPA

56LH93261Y

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1962

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha

DOPA decarboxylase

Adrenergic receptor alpha

Conditions:

Type 1 diabetes in DQ8 positive patients with residual beta cell function

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble an...

d stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

METHYLDOPATE HYDROCHLORIDE

7PX435DN5A

Export Data
Search for Structure

Status:

US Approved Rx (1985)

First approved in 1962

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha

DOPA decarboxylase

Adrenergic receptor alpha

Conditions:

Type 1 diabetes in DQ8 positive patients with residual beta cell function

Methyldopate hydrochloride [levo-3-(3,4-dihydroxyphenyl)-2-methylalanine, ethyl ester hydrochloride] is the ethyl ester of methyldopa, supplied as the hydrochloride salt with a molecular weight of 275.73. Methyldopate hydrochloride is more soluble an...

d stable in solution than methyldopa and is the preferred form for intravenous use. Methyldopate hydrochloride is an alpha adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1